NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

Rhea-AI Summary

NeuroRx and TFF Pharmaceuticals (NASDAQ: TFFP) have signed a Feasibility Agreement, enabling the transfer of ZYESAMI™ materials to TFF for formulation work. This aims to develop a stable dry powder version of ZYESAMI™, enhancing aerosol delivery to the lungs. ZYESAMI™ is a synthetic peptide that aids in treating lung conditions linked to COVID-19 by potentially increasing surfactant production. The collaboration seeks to broaden its therapeutic applications, particularly for patients with varying severity of COVID-19 symptoms.

Positive

• Collaboration with NeuroRx may lead to an improved formulation of ZYESAMI™, enhancing its market potential.
• ZYESAMI™ has shown a significant reduction in hospital discharge time for severely ill COVID-19 patients, indicating promising efficacy.

Negative

• None.

NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement). Under the Feasibility Agreement, NeuroRx is delivering ZYESAMI™ (aviptadil, synthetic VIP) materials to TFF in order to perform feasibility formulation work and testing. The goal of this feasibility work is to formulate and identify an optimal, long-term stable formulation of ZYESAMI™ into a dry powder form, which has superior aerosol properties for delivery directly to the lungs.

ZYESAMI is a synthetic form of a naturally occurring peptide found in the lung called Vasoactive Intestinal Peptide (VIP), which is known to protect the Alveolar Type II cell that is targeted by the SARS-CoV-2 virus. The symptoms of COVID-19 are attributable to decreased surfactant production and increased cytokine production caused by Coronavirus infection of the Type II cell. This may also be a common pathway in sepsis-induced Acute Respiratory Distress Syndrome (ARDS) and Checkpoint Inhibitor induced pneumonitis associated with certain cancer drugs.

Loss of surfactant production in the lung may be the direct cause of the profound hypoxia or respiratory failure seen in COVID-19. The ability to deliver VIP directly to the lung via inhalation could have important therapeutic implications and potentially broaden the application of the drug to patients less severely affected with COVID-19.

“We are excited that ZYESAMI has demonstrated a highly significant reduction in time to hospital discharge for seriously ill COVID-19 patients treated with High Flow Nasal Oxygen, along with an increased likelihood of recovery and excellent safety,” said Jonathan C. Javitt, M.D., M.P.H., CEO of NeuroRx. “Although o

FAQ

What is the Feasibility Agreement between NeuroRx and TFF Pharmaceuticals?

The Feasibility Agreement allows NeuroRx to deliver ZYESAMI™ materials to TFF for formulation and testing to create a dry powder form for better lung delivery.

What is ZYESAMI™ and how does it relate to COVID-19?

ZYESAMI™ is a synthetic peptide that protects lung cells affected by COVID-19, potentially improving surfactant production and respiratory function.

What are the expected outcomes of the TFFP and NeuroRx collaboration?

The collaboration aims to develop a long-term stable formulation of ZYESAMI™ that enhances aerosol delivery, potentially broadening its applications for COVID-19 treatment.

How has ZYESAMI™ performed in clinical settings?

ZYESAMI™ has significantly reduced hospital discharge times for seriously ill COVID-19 patients while maintaining excellent safety.